A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Metenkefalin/tridecactide (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Bosnalijek
- 13 Aug 2024 Status changed from recruiting to discontinued. (During the Covid-19 pandemic, the study was unable to enroll further patients.)
- 07 Feb 2023 Planned End Date changed from 31 Mar 2023 to 1 Jul 2024.
- 07 Feb 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Dec 2023.